secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001493152-25-022631
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma reports Q3 2025 net loss of $3.1M; cash $2.6M funds into Q1 2026
-----------------------------------------------------------------------------

- Net loss of $3.1M for Q3 2025 improved from $3.4M in Q3 2024.
- Cash and equivalents $2.6M expected to fund operations into Q1 2026.
- R&D expenses fell to $0.6M from $1.3M due to lower production and material costs.
- Phase 1 GTB-3650 trial now in Cohort 4 at 10 µg/kg/day; next update Q1 2026.
- GTB-5550 IND submission for B7H3 tumors expected late Dec 2025 or Jan 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315225022631/0001493152-25-022631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315225022631/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer